Background. HIV research is a therapeutic area for which welldefined populationspecific treatment and prophylaxis guidelines exist. However, there are limited objective, evidencebased data for assessing adherence to these guidelines. Objective. To conduct a retrospective, crosssectional study of adult HIVinfected patients receiving treatment at the antiretroviral (ARV) rollout clinic of the Infectious Diseases Clinic Pharmacy at 1 Military Hospital (1MH) over a period of 3 years to assess clinicians' adherence to the 2010 ARV guidelines. Methods. Pharmacy files from the pool of adult patients receiving treatment at the ARV rollout clinic between 1 April 2009 and 31 March 2012 were selected. Variables used to establish adherence were assessed through evaluation of pharmacy scripts and laboratory tests. Results. In accordance with the ARV guidelines, we found a switch in the firstline regimen from stavudine to tenofovir during the period following implementation. There was no difference in baseline blood tests conducted, suggesting that clinicians were recommending a standardised test panel. Notably, similar blood tests were routinely done during followup visits, despite no indication for doing so. While the number of blood tests was found to decrease over time, the type of blood tests requested for specific treatment regimens was not in accordance with the ARV guidelines. Conclusion. We used an evidencebased approach to critically assess variations from the delineated ARV guidelines. Adherence to clinical guidelines at 1MH, while demonstrating improvement in patient outcomes, highlighted the need for increased vigilance in monitoring failure of prescribers to comply with ARV guidelines.
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Advances in management and treatment of HIV/ AIDS have transformed HIV into a chronic condition rather than a debilitating terminal illness. Data on patient adherence suggest positive outcomes provi ded there is >95% compliance with therapy. [1] Welldefined, populationspecific treatment and prophylaxis guidelines for treatment of HIV exist, [1] which integrate scientific evidence and clinical expertise to produce clinically valid, operational recommendations with the aim of improving various health outcomes. These clinical practice guidelines can be defined as systematically developed statements for both practitioners and patients, to assist with appropriate healthcare decisions for specific clinical circumstances. [2] Their intention is to improve healthcare processes, decrease practice variation and optimise use of resources to improve health outcomes.
However, studies reveal widespread variability among practit ioners, notably in specialised domains with respect to adher ence to the core recommendations of various practice guidelines. [3] Antiretroviral treatment (ART), in the form of highly active anti retroviral therapy, consists of a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonNRTI or a protease inhibitor. The South African (SA) 2004 antiretroviral (ARV) guidelines recommended a combination of stavudine (d4T) and lamivudine (3TC) as the NRTI backbone in the firstline regimen and a combination of zidovudine (AZT) and didanosine (DDI) as the backbone in the secondline regimen. [4] Unfortunately, both d4T
and DDI were found to be major culprits in the onset of metabolic toxicities and became further implicated in development of fatal complications such as lactic acidosis. [5, 6] Currently SA has the largest HIV treatment programme in the world, with ~1.3 million people receiving ART by the end of 2010. [7] However, burdensome adverse effects, although varying in their impact, have concerned government, healthcare providers and patients alike. As a result, the 2010 ARV guidelines focused on curbing morbidity and mortality associated with d4T and DDI. These and subsequent guidelines suggested replacing d4T and DDI with less toxic alternatives such as tenofovir (TDF) as the firstline regimen and 3TC as the secondline regimen.
The [8] Ordinarily, subjective approaches such as interviews and selfreport questionnaires by clinicians themselves are used to determine adherence to guidelines and success of therapeutic endeavours. There are limited published data, both locally and internationally, for assessing adherence to these guidelines using objective evidence based approaches such as assessing prescrip tions and the choice of laboratory tests associated with specific drug regimens, as delineated in the guidelines. [1] The aim of this study was to assess com pliance with the 2010 ARV guidelines to determine the degree of guideline imple mentation and provide insight into changes required to strengthen subsequent guideline implementation. 
Methods

Ethical approval
Study design
A retrospective, crosssectional study of adult HIVinfected patients receiving treatment prescriptions and management at the ARV rollout clinic of the Infectious Diseases Clinic Pharmacy at 1MH over a period of 3 years, to assess clinicians' adherence to the 2010 ARV guidelines through the evaluation of pharmacy scripts and laboratory tests ordered.
Data collection
Approximately 300 pharmacy files from the pool of adult patients receiving ART between 1 April 2009 and 31 March 2012 were selected using a predetermined randomisation system. From the 300 randomised adult patient files selected, 252 met the inclusion criteria (>18 years of age and continuing to receive ART).
The files were subsequently divided into three patient categories: 
Laboratory tests
Data regarding laboratory tests were extracted from the hospital computer system. All laboratory tests requested by doctors during patient visits at baseline and during subsequent monitoring visits were done by 1MH. Laboratory tests routinely requested included full blood count (FBC); urea and electrolytes (U&E); liver function tests (LFTs) (total protein, albumin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase and γglutamyl transpeptidase), hepatitis B serology; CD4 + count and HIV viral load (VL). Laboratory tests, each highly drug specific, were assessed to determine whether the correct suggested blood tests, and timing of their monitoring, were done as recommended by the 2010 guidelines. For example, FBC is recommended at 1, 2, 3 and 6 months if the patient is receiving AZT; creatinine needs be monitored at months 3 and 6, and thereafter annually, if the patient is receiving TDF; and fasting cholesterol and triglycerides monitored at month 3 if the patient is receiving Aluvia (lopinavir/ritonavir; Abbott Laboratories), and then annually thereafter. [9] 
Statistical analysis
Descriptive statistics for categorical data were summarised and tabulated while mean and/or median values were calculated for continuous variables such as age. Analysis of variance was used to compare drugs in the first and secondline regimens during the analysis period (between the two periods and among the groups, respectively, where required). Fisher's exact test was used to compare mean values for blood tests, time intervals and CD4 + count outcome variables during the analysis period (between the two periods and among the groups, respectively, where required). Statistical analysis was done using SAS 9.2 statistical software, with pvalues of <0.05 considered statistically significant.
Results
Demographic characteristics are summarised in Table 1 . Of note, the number of men receiving treatment was higher in all three groups.
When assessing the predominant drugs used over the duration of this study (Tables 2 and 3) , it was noted that the mean number of d4T prescriptions used in firstline regimens declined significantly in all groups (p<0.001). There was a resultant decrease of 21 scripts when comparing pre2010 data with an average of the three groups, postimplementation of the 2010 ARV guidelines. Use of TDF was limited prior to introduction of the 2010 guideline, with a subsequent statistically significant (p<0.001) increase within the years following implementation of the 2010 guidelines. This resulted in an increase of 25 scripts when comparing pre2010 data with an average of the three groups postimplementation.
These data also describe the decline in DDI use (p<0.001), which was no longer recommended. While there was no significant difference (p<0.145) in 3TC across the groups, owing to its use in both first and second line regimens, there was a trend suggesting a preference for the fixeddose combination of Truvada (emtricitabine and TDF; Gilead Sciences, USA) over TDF with 3TC in the later stages of the study.
According to the 2010 ARV guidelines, the CD4 + criterion for initiation was ≤200 cells/μl, with the exception of special cohorts of patients presenting with pregnancy or tuberculosis (TB), who were initiated on therapy with CD4 + counts <350 cells/μl. The number of patients with CD4
+ counts ≤200 cells/μl or 200 350 cells/μl, both preand postApril 2010, including the special cohorts, was therefore compared. This yielded no significant differences in the nonspecialised population (p=1.00), pregnant women (pvalue not applicable owing to small sample size), or patients with TB (p=0.233 and 0.466, respectively, before and after guideline implementation).
Baseline tests conducted regularly included FBC, U&E, LFTs, CD4 + count, VL and, in a minority population where warranted, hepatitis B serology. Comparing baseline blood tests conducted pre and post implementation using a χ 2 test, there was no statistically significant difference. This suggested that clinicians were recommending a standard panel of tests to which they had become accustomed.
The number of blood tests done for newly initiated patients, and for those already receiving treatment, was the same at baseline regardless of the drug regimen ( Table 4 ). The same blood tests done at initiation were routinely done during followup, despite there being no guideline indication for doing so. However, omission of LFTs and hepatitis B serology was adhered to, as recommended in the ARV guidelines.
Assessment of the time interval in months for followup monitor ing visits revealed that the choice of blood tests was similar across all regimens. Only in group 3, and 2 years postimplementation of the 2010 guidelines, was a slightly more drugdependent approach observed regarding prescription of TDF and d4T and timing of blood tests ( Table 5) .
The most prevalent sideeffects ( Table 6 ) that resulted in drug substitution included hepatotoxicity, peripheral neuropathy and lipodystrophies and lipoatrophies, most often associated with d4T. Additional reasons for d4T substitution included virological failure, which was higher in groups 1 and 2 and involved 12 and eight patients, respectively, compared with only three patients in group 3 (which was probably associated with the decreased use of d4T to comply with the 2010 guidelines).
Additionally, ten, 11 and two patients in groups 1, 2 and 3, respectively, substituted d4T with TDF or Truvada to comply with the 2010 guidelines. Survival analysis indicated that patients in group 3 required changes in treatment due to treatment failure at a much later stage than patients in groups 1 and 2. Time taken in months to comply with the new guidelines of 1 April 2010 was measured by determining the time required for d4T to be replaced by TDF in the firstline regimen, and DDI by 3TC in the secondline regimen. In the firstline regimen, only patients who substituted drugs on the basis of complying with the new guidelines were considered, substitutions due to sideeffects being excluded. The decrease in d4T and increase in TDF scripts for firstline regimens occurred in groups 2 and 3, at least 1 year postimplementation.
In the secondline regimen, substitution to 3TC followed development of virological failures as recommended in new guidelines made available during the study. From the time of introduction of the new guidelines, which was considered baseline, an average of 2.42 scripts for DDI were given in group 2, which was already a year after implementation of the new guidelines. However, in compliance with the guidelines, zero scripts for DDI were dispensed for group 3 (2011 2012), with, however, a delay of over a year for DDI prescrip tions to cease completely.
Discussion
In the year prior to implementation of the 2010 guidelines, d4T prescriptions were high, with 590 prescriptions dispensed v. only 50 for TDF in the same time period. This paradigm began to shift within the first year of the new ARV guidelines. A striking rise in the choice of Truvada over the single TDF and 3TC was observed, which may be expected to increase in the years to come.
According to the 2010 guidelines, the recommended blood tests at baseline include CD4 + count, haemoglobin (Hb) or FBC if starting on AZT, serum creatinine if TDF is considered, and ALT if nevirapine (NVP) is initiated. The 2010 guidelines suggested that VL and CD4 + count be done only during monitoring of treatment at 6 months, then at 12 months, and thereafter at annual intervals. [8] Hepatitis screening was not included in the 2010 guidelines; however, the 2013 guidelines included hepatitis screening at baseline, with ALT required only if the patient was prescribed NVP and developed rash or symptoms of hepatitis. [9] On average, tests for monitoring were conducted more frequently than indicated in the guidelines. Baseline tests ordered at the clinic were excessive, and did not take into account the choice of initial drug/s prescribed. There was no difference in the number or types, of blood tests ordered for the d4Tbased regimens before and after implementation of the 2010 guidelines. While timing intervals of blood tests for AZTbased regimens more closely complied with guidelines in the last year of the study, there was no evidence of Hb or FBC measured monthly for the first 3 months for patients newly initiated on AZT, as per recommendation. The d4Tbased regimen had 619 blood tests for each of FBC and LFTs, not all of which were indicated; however, ALT was warranted if the regimen included NVP and symptoms of hepatitis became evident. There were 225 unjustified FBCs and LFTs in patients receiving the TDFbased regimen over the same period. It was also noted that an average of three blood tests were routinely done for abacavir, which has no known sideeffects warranting blood test monitoring. These unnecessary tests incurred significant costs.
Patients in all three groups on Aluviabased regimens had no blood tests done for fasting cholesterol and triglycerides to monitor the sideeffects of these drugs, despite their recommendation in the new guidelines. This potentially places patients at risk of developing dyslipidaemias, and cardiovascular events, which are strongly associated with this drug.
The 2010 guidelines clearly stated that ART be initiated at a CD4 + count ≤200 cells/μl with the exception of pregnancy and TB, where the CD4 + count for starting treatment is 350 cells/μl. [8] (Within the 2013 guidelines, SA has fully implemented the new CD4 + count criteria where the level of CD4 + count for initiation is ≤350 copies/μl, and at any CD4 + count where TB or pregnancy is present.) It was not surprising to see that there were no pregnant women with a CD4 count <200 copies/μl, because at 1MH all HIVpositive pregnant women are placed on ARV treatment regardless of CD4 + count as part of the prevention of mothertochild transmission programme. Following delivery, those eligible for ARV treatment continue while treatment is discontinued in those not eligible. TB patients continue to present very late in their disease course, when the CD4 + count is already very low; hence only 10 patients had CD4 + counts of 200 350 copies/μl at initiation v. 23 patients with <200 copies/μl. TDF was already being dispensed at 1MH by the time the new 2010 guidelines were implemented, but was reserved for patients experiencing sideeffects of d4T. However, implementation was associated with an impressive decline in sideeffects, implying that the rising use of TDF was yielding positive patient outcomes with potentially lower numbers of patients experiencing treatment failure.
Study limitation
This study was conducted at only one site.
Conclusion
The lifespan of HIV patients receiving ARV treatment is improving, but risk factors associated with longterm drug treatment are increasing. This is one of the first studies in SA to use objective evidencebased approaches to critically assess variance from ARV guidelines to determine compliance on the part of prescribing clinicians.
We found that compliance to ARV guidelines at the rollout clinic at 1MH was satisfactory in some areas and not in others. Improvement in patient outcomes was demonstrated by a declining number of sideeffects, most notably in the firstline regimen where TDF demonstrated a greater tolerability than d4T. However, an increased need for vigilance is required with regard to blood test monitoring, where clinicians fail to comply with the ARV guidelines. Addressing these issues may significantly alleviate the financial burden faced by healthcare organisations.
